Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with wet Age-related Macular Degeneratio
- Conditions
- Exudative Age-related Macular DegenerationTherapeutic area: Diseases [C] - Eye Diseases [C11]MedDRA version: 14.1Level: LLTClassification code 10025411Term: Macular degeneration senileSystem Organ Class: 10015919 - Eye disorders
- Registration Number
- EUCTR2011-002526-43-AT
- Lead Sponsor
- Allergan Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 204
Inclusion Criteria
1. active exudative age-related macular degeneration
2. best-corrected visual acuity between 20/40 and 20/320
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 184
Exclusion Criteria
1. Females who are pregnant, nursing, or of child-bearing potential and not on
adequate birth control
2. near-sightedness of 8 diopters or more
3. glaucoma
4. cataract surgery or Lasik within the last 3 months
5. any active ocular infection or inflammation
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method